This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
BBS-Bioactive Bone Substitutes Oyj Future Growth
Future criteria checks 0/6
Key information
-1.7%
Earnings growth rate
-1.8%
EPS growth rate
Biotechs earnings growth | 37.7% |
Revenue growth rate | 97.3% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 03 Feb 2023 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 3 | -3 | -4 | -3 | 1 |
12/31/2024 | 1 | -4 | -4 | -4 | 1 |
12/31/2023 | N/A | -4 | -5 | -4 | 1 |
12/31/2022 | 0 | -3 | -3 | -3 | N/A |
9/30/2022 | 0 | -3 | -3 | -3 | N/A |
6/30/2022 | N/A | -3 | -3 | -3 | N/A |
3/31/2022 | N/A | -3 | -3 | -3 | N/A |
12/31/2021 | N/A | -3 | -3 | -3 | N/A |
9/30/2021 | N/A | -3 | -3 | -3 | N/A |
6/30/2021 | N/A | -3 | -3 | -3 | N/A |
3/31/2021 | N/A | -3 | -3 | -3 | N/A |
12/31/2020 | N/A | -3 | -2 | -2 | N/A |
9/30/2020 | N/A | -2 | -2 | -2 | N/A |
6/30/2020 | N/A | -2 | -2 | -2 | N/A |
3/31/2020 | N/A | -2 | -2 | -2 | N/A |
12/31/2019 | N/A | -2 | -1 | -1 | N/A |
9/30/2019 | N/A | -2 | -1 | -1 | N/A |
6/30/2019 | N/A | -2 | -1 | -1 | N/A |
3/31/2019 | N/A | -1 | -2 | -2 | N/A |
12/31/2018 | N/A | 0 | -2 | -2 | N/A |
9/30/2018 | N/A | -1 | -2 | -2 | N/A |
6/30/2018 | N/A | -3 | -2 | -2 | N/A |
3/31/2018 | N/A | -4 | -2 | -1 | N/A |
12/31/2017 | N/A | -4 | -1 | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BONES is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BONES is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BONES is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BONES is forecast to have no revenue next year.
High Growth Revenue: BONES is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BONES's Return on Equity is forecast to be high in 3 years time